Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has 3 years of Other Non-Current Liabilities data on file, last reported at $9000.0 in Q1 2022.

• Other Non-Current Liabilities for Q1 2022 came in at $9000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $9000.0 (changed N/A YoY), and the FY2021 annual result was $17000.0, down 90.34% from the prior year.
• Other Non-Current Liabilities declined to $9000.0 in Q1 2022 per CRBU's latest filing, from $17000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $176000.0 in Q4 2020 and troughed at $9000.0 in Q1 2022.
• A 3-year average of $103600.0 and a median of $153000.0 in 2021 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 90.34% in 2021 and fell as far as 90.34% in 2021.
• A 3-year view of Other Non-Current Liabilities shows it stood at $176000.0 in 2020, then plunged by 90.34% to $17000.0 in 2021, then slumped by 47.06% to $9000.0 in 2022.
• Business Quant data shows CRBU's Other Non-Current Liabilities at $9000.0 in Q1 2022, $17000.0 in Q4 2021, and $153000.0 in Q3 2021.